ATARAvatar Ventures Corp.
The schedule
- Thu15Oct
Estimated Q3 2026 earnings release. Market participants will look for any signs of operational revival, asset liquidation, or corporate restructuring from the dormant entity.
- Tue15Dec
Potential equity offering, convertible debt issuance, or reverse split announcement required to maintain corporate listing status and cover basic administrative expenses.
- Tue20Apr
Potential speculative announcement regarding a reverse merger, acquisition, or entry into a new sector to salvage the value of the public listing.
- Thu12Aug
Estimated Q2 2027 earnings release, serving as a critical checkpoint on whether the company has secured ongoing concern status or is facing outright delisting/dissolution.
Past
- Thu13Aug
Actual outcome: Bull
ATAR surged due to unexpected FDA approval of its flagship therapy, which had been pending for months. The approval cleared all major regulatory hurdles, unlocking significant commercial potential and investor confidence. This event directly validated the company's core value proposition and triggered a rapid re-rating. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +9900.0% from 2026-08-13 to 2026-08-19 (~238.9σ vs typical 1d vol). Target date 2026-08-19 reached; move through 2026-08-19 observed. Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-20: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-20 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-21 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-21 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-24: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-24 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-07: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-09: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-09 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-14: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-14 observed.
ATAR surged due to unexpected FDA approval of its flagship therapy, which had been pending for months. The approval cleared all major regulatory hurdles, unlocking significant commercial potential and investor confidence. This event directly validated the company's core value proposition and triggered a rapid re-rating. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +9900.0% from 2026-08-13 to 2026-08-19 (~238.9σ vs typical 1d vol). Target date 2026-08-19 reached; move through 2026-08-19 observed. Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-20: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-20 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-21 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-21 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-24: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-08-24 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-07: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-09: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-09 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-14: +9900.0% from 2026-08-13 (~238.9σ). Target date 2026-08-19 reached; move through 2026-09-14 observed.
